Gamma globulin

(Redirected from Gammopathy)
Jump to navigation Jump to search
Schematic representation of a protein electrophoresis gel

WikiDoc Resources for Gamma globulin

Articles

Most recent articles on Gamma globulin

Most cited articles on Gamma globulin

Review articles on Gamma globulin

Articles on Gamma globulin in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Gamma globulin

Images of Gamma globulin

Photos of Gamma globulin

Podcasts & MP3s on Gamma globulin

Videos on Gamma globulin

Evidence Based Medicine

Cochrane Collaboration on Gamma globulin

Bandolier on Gamma globulin

TRIP on Gamma globulin

Clinical Trials

Ongoing Trials on Gamma globulin at Clinical Trials.gov

Trial results on Gamma globulin

Clinical Trials on Gamma globulin at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Gamma globulin

NICE Guidance on Gamma globulin

NHS PRODIGY Guidance

FDA on Gamma globulin

CDC on Gamma globulin

Books

Books on Gamma globulin

News

Gamma globulin in the news

Be alerted to news on Gamma globulin

News trends on Gamma globulin

Commentary

Blogs on Gamma globulin

Definitions

Definitions of Gamma globulin

Patient Resources / Community

Patient resources on Gamma globulin

Discussion groups on Gamma globulin

Patient Handouts on Gamma globulin

Directions to Hospitals Treating Gamma globulin

Risk calculators and risk factors for Gamma globulin

Healthcare Provider Resources

Symptoms of Gamma globulin

Causes & Risk Factors for Gamma globulin

Diagnostic studies for Gamma globulin

Treatment of Gamma globulin

Continuing Medical Education (CME)

CME Programs on Gamma globulin

International

Gamma globulin en Espanol

Gamma globulin en Francais

Business

Gamma globulin in the Marketplace

Patents on Gamma globulin

Experimental / Informatics

List of terms related to Gamma globulin


Overview

Gamma globulins, or Ig's, are a class of proteins in the blood, identified by their position after serum protein electrophoresis. The most significant gamma globulins are immunoglobulins.

Injections

Gamma globulin injections are usually given in an attempt to temporarily boost a patient's immunity against disease. Injections are most commonly used on patients who have been exposed to hepatitis A or measles, or to make a donor and a kidney recipient compatible regardless of blood type of tissue match. Injections are also used to boost immunity in patients who lack the ability to produce gamma globulins because of an immune deficiency, such as X-linked agammaglobulinemia and hyper IgM syndrome. Such injections are less common in modern medical practice than they were previously, and injections of gamma globulin previously recommended for travelers have largely been replaced by the use of hepatitis A vaccine.

Gamma globulin infusions are also used to treat immunological diseases, such as idiopathic thrombocytopenia purpura (ITP), a disease in which the platelets are being attacked by antibodies, leading to seriously low platelet counts. Gamma globulin apparently causes the spleen to ignore the antibody-tagged platelets, thus allowing them to survive and function.

Gamma globulin injections also provide substantial benefit to many suffering from Chronic Fatigue Syndrome, also known as Chronic Fatigue and Immune Disfunction Syndrome; Mylagic Encyphalitis; Chronic Epsteinn-Barr; Chronic Mono. In particular, it helps those who are greatly affected by changes in the barometric pressure (i.e., change in weather conditions, especially rain or other storms).

Another theory on how gamma globulin administration works in autoimmune disease is by overloading the mechanisms which degrade gamma globulins. Over loading the degradation mechanism causes the harmful gamma globulins to have a much shorter halflife in sera.

Pathology

An excess is known as hypergammaglobulinemia.

A disease of gamma globulins is called a "gammopathy" (for example, in monoclonal gammopathy of undetermined significance.)

Disease treatments

Kidney Transplant: Intravenous Gamma globulin was FDA approved in 2004 to reduce antibodies in a patient in kidney failure to allow that person to accept a kidney from a donor who has a different blood type, (ABO incompatible) or is an unacceptable tissue match. Dr. Stanley Jordan at Cedars-Sinai Medical Center in Los Angeles pioneered this treatment.

External links

Template:WH Template:WikiDoc Sources